L3VLUP
ProSign in

MNKD in the 13F filings

Mannkind Corp · CUSIP 56400P706

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2025Q1 2025Q4 2024Q3 2024Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Quarter end
30 Sep 2022
the date the book describes
Filed
14 Nov 2022
latest of these filings; the earliest 14 Nov 2022
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2022 and Q3 2022; 2 listed it in both
Shares listed
5,610,229
combined, among listed positions
Reported value
$17m
combined, at the quarter end

Managers listing MNKD in Q3 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Schonfeld Strategic Advisors LLC2,779,232$8.6m0.07%Added+341,60314 Nov 2022 (the filing on sec.gov)
Woodline Partners LP1,849,389$5.7m0.08%Newnew14 Nov 2022 (the filing on sec.gov)
Walleye Capital LLC981,608$3.0m0.06%Added+513,06814 Nov 2022 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2022 to Q3 2022, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2022 to 2 in Q2 2025

Tracked managers listing it, at least.

02462021202220232025
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
MNKD by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20171$369kn.a.n.a.
Q3 20172$1.6mn.a.n.a.
Q4 20171$706kn.a.n.a.
Q2 20202$339kn.a.n.a.
Q1 20211$5.5mn.a.n.a.
Q2 20211$13mn.a.n.a.
Q3 20212$6.4mn.a.n.a.
Q4 20211$5.9mn.a.n.a.
Q1 20223$6.0mn.a.n.a.
Q2 20222$11mn.a.n.a.
Q3 20223$17mn.a.n.a.
Q4 20222$19mn.a.n.a.
Q1 20231$7.5mn.a.n.a.
Q2 20231$2.0mn.a.n.a.
Q3 20243$25m30
Q4 20245$72m31
Q1 20252$23m20
Q2 20252$13m11

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

MNKD and LLY →MNKD and JNJ →MNKD and VRTX →Choose a stock to compare with MNKD →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own MNKD, latest filings →Back to the 13F Explorer →